Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________ FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35092 _____________________________________________________________________________ ...

Investor Contact: Derek Leckow Exact Sciences Corp. investorrelations@exactsciences.com 608-893-0009 Media Contact: Steph Spanos Exact Sciences Corp. sspanos@exactsciences.com 608-556-4380 For Immediate Release Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results Fourth quarter and 2025 highlights MADISON, Wis., Feb. 13, 2026 — Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $878 mill ...

Core Insights - Exact Sciences Corp. reported revenue of $878 million for Q4 2025 and $3.25 billion for the full year 2025, both ending December 31, 2025 [1] Group 1: Financial Performance - The company achieved a revenue of $878 million in the fourth quarter of 2025 [1] - For the full year 2025, Exact Sciences generated a total revenue of $3.25 billion [1] Group 2: Operational Highlights - In 2025, Exact Sciences screened more individuals than ever before, contributing to personalized treatment decisions [1] - The company successfully launched three new tests during the year [1]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

ST. LOUIS--(BUSINESS WIRE)--Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued a Final Written Decision following inter partes review (IPR), finding all 10 challenged claims of Exact Sciences' U.S. Patent No. 11,970,746 (the '746 patent) unpatentable. This decision follows the PTAB's July 2025 Final Written. ...

Core Viewpoint - Exact Sciences Corp. celebrates the passage of federal legislation that will enable Medicare coverage for multi-cancer early detection (MCED) tests, addressing a significant gap in cancer screening [1] Group 1: Legislative Impact - The new legislation establishes a pathway for Medicare to cover MCED tests, which is crucial for early cancer detection [1] - Nearly 70% of annual cancer cases and deaths in the U.S. occur in cancers that currently have no recommended screening [1] Group 2: Industry Context - Cancer remains the second leading cause of death in the U.S., highlighting the urgent need for improved screening methods [1]

Core Insights - Exact Sciences Corp. has achieved a significant milestone with its Oncotype DX Breast Recurrence Score® test, as over two million breast cancer patients globally have utilized the test to inform their treatment decisions [1] Company Overview - Exact Sciences Corp. is recognized as a leading provider of cancer screening and diagnostic tests [1] - The Oncotype DX Breast Recurrence Score® test is supported by more than two decades of clinical evidence, establishing it as a global standard-of-care [1]

Baron Funds, an investment management company, released its “Baron Discovery Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Fund focuses on long-term, competitively positioned companies that are well-managed and have significant potential in untapped markets. The letter also addressed the advancements in AI and how humans define themselves in the changing landscape. In Q4, the fund generated a return of 0.19% (Institutional Shares), underperforming the Russell 2 ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Viewpoint - Investors in the Medical - Biomedical and Genetics sector should consider Exelixis (EXEL) and Exact Sciences (EXAS) for potential value opportunities, with a closer examination needed to determine which stock offers better value [1] Valuation Metrics - Exelixis has a Zacks Rank of 2 (Buy), indicating a more favorable earnings estimate revision trend compared to Exact Sciences, which has a Zacks Rank of 3 (Hold) [3] - The forward P/E ratio for EXEL is 13.46, significantly lower than EXAS's forward P/E of 73.35, suggesting EXEL may be undervalued [5] - EXEL's PEG ratio is 0.69, while EXAS has a PEG ratio of 2.42, indicating that EXEL's expected earnings growth is more attractive relative to its price [5] - EXEL has a P/B ratio of 5.41 compared to EXAS's P/B of 7.76, further supporting EXEL's more favorable valuation metrics [6] Investment Conclusion - Given the stronger estimate revision activity and more attractive valuation metrics, EXEL is positioned as the superior option for value investors at this time [7]